Study of Acalabrutinib and Tafasitamab in MZL Patients
Clinical trial NCT04646395 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04646395
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-20
- Primary completion
- 2027-09-15
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.